Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Donata Medaglini; Claire-Anne Siegrist

doi:10.1016/j.coviro.2017.03.008

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Curr Opin Virol. 2017 Apr:23:88-94. doi: 10.1016/j.coviro.2017.03.008. Epub 2017 Apr 28.

Authors

Donata Medaglini¹, Claire-Anne Siegrist²

Affiliations

¹ Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
² World Health Organization Collaborating Center for Vaccine Immunology, Departments of Pathology-Immunology, University of Geneva, 1211 Geneva, Switzerland. Electronic address: claire-anne.siegrist@unige.ch.

PMID: 28460340
DOI: 10.1016/j.coviro.2017.03.008

Abstract

The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.

Publication types

Review

MeSH terms

Drug Carriers
Ebola Vaccines / administration & dosage
Ebola Vaccines / immunology*
Ebolavirus / immunology*
Gene Expression Profiling
Hemorrhagic Fever, Ebola / prevention & control*
Humans
Immunoassay
Metabolome
Vaccines, Synthetic / administration & dosage
Vaccines, Synthetic / immunology
Vesiculovirus / genetics

Substances

Drug Carriers
Ebola Vaccines
Vaccines, Synthetic